Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data.

The objective of this article was to review and summarize the available reports on the preclinical profile of the novel anticonvulsant drug levetiracetam (LEV). Therefore, a careful search was conducted in the MEDLINE database and combined with guidelines from regulatory agencies, proceedings of professional scientific meetings, and information provided by the manufacturers. This article provides detailed information on the anticonvulsant effects of LEV in various animal models of epilepsy and on its pharmacology in laboratory animals. The mechanism of action of LEV is reviewed, with special regard to its recently discovered binding site, the synaptic vesicle protein 2A. In general, LEV is shown to be a safe, broad-spectrum anticonvulsant drug with highly beneficial pharmacokinetic properties and a distinct mechanism of action. The clinical studies with LEV will be discussed in the second part of this review article to be published subsequently.

[1]  Hannah R Cock,et al.  Administration of Levetiracetam after prolonged status epilepticus does not protect from mitochondrial dysfunction in a rodent model , 2007, Epilepsy Research.

[2]  P. Calabresi,et al.  Multiple Mechanisms Underlying the Neuroprotective Effects of Antiepileptic Drugs Against In Vitro Ischemia , 2006, Stroke.

[3]  M. Gillard,et al.  Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. , 2006, European journal of pharmacology.

[4]  M. Walker,et al.  Levetiracetam: Antiepileptic Properties and Protective Effects on Mitochondrial Dysfunction in Experimental Status Epilepticus , 2006, Epilepsia.

[5]  N. S. Austin,et al.  Synaptic Vesicle Protein 2 Enhances Release Probability at Quiescent Synapses , 2006, The Journal of Neuroscience.

[6]  P. Patsalos,et al.  Pharmacodynamic and Pharmacokinetic Characterization of Interactions between Levetiracetam and Numerous Antiepileptic Drugs in the Mouse Maximal Electroshock Seizure Model: An Isobolographic Analysis , 2006, Epilepsia.

[7]  P. Patsalos,et al.  Levetiracetam selectively potentiates the acute neurotoxic effects of topiramate and carbamazepine in the rotarod test in mice , 2005, European Neuropsychopharmacology.

[8]  S. Theander,et al.  SV2A and SV2C are not vesicular Ca2+ transporters but control glucose-evoked granule recruitment , 2005, Journal of Cell Science.

[9]  R. Raedt,et al.  Rapid kindling in preclinical anti-epileptic drug development: The effect of levetiracetam , 2005, Epilepsy Research.

[10]  R. M. Freitas,et al.  Evaluation of levetiracetam effects on pilocarpine-induced seizures: Cholinergic muscarinic system involvement , 2005, Neuroscience Letters.

[11]  Tadao Serikawa,et al.  Long‐lasting Antiepileptic Effects of Levetiracetam against Epileptic Seizures in the Spontaneously Epileptic Rat (SER): Differentiation of Levetiracetam from Conventional Antiepileptic Drugs , 2005, Epilepsia.

[12]  R. Raedt,et al.  Chronic levetiracetam treatment early in life decreases epileptiform events in young GAERS, but does not prevent the expression of spike and wave discharges during adulthood , 2005, Seizure.

[13]  T. Serikawa,et al.  Separation of Antiepileptogenic and Antiseizure Effects of Levetiracetam in the Spontaneously Epileptic Rat (SER) , 2005, Epilepsia.

[14]  A. Kaindl,et al.  Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain , 2005, Experimental Neurology.

[15]  M. Cataldi,et al.  The Antiepileptic Drug Levetiracetam Decreases the Inositol 1,4,5-Trisphosphate-Dependent [Ca2+]i Increase Induced by ATP and Bradykinin in PC12 Cells , 2005, Journal of Pharmacology and Experimental Therapeutics.

[16]  Brigitte M. Bouwman,et al.  Effects of levetiracetam on spike and wave discharges in WAG/Rij rats , 2004, Seizure.

[17]  A. Hufnagel,et al.  Levetiracetam inhibits Na+‐dependent Cl−/HCO3− exchange of adult hippocampal CA3 neurons from guinea‐pigs , 2004, British journal of pharmacology.

[18]  W. Löscher,et al.  Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats , 2004, Neuroreport.

[19]  M. Brodie,et al.  Pharmacodynamic interaction studies with topiramate in the pentylenetetrazol and maximal electroshock seizure models , 2004, Seizure.

[20]  P. Calabresi,et al.  Intracellular Calcium Increase in Epileptiform Activity: Modulation by Levetiracetam and Lamotrigine , 2004, Epilepsia.

[21]  K. Nocka,et al.  The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. Bolwig,et al.  Levetiracetam prevents changes in levels of brain-derived neurotrophic factor and neuropeptide Y mRNA and of Y1- and Y5-like receptors in the hippocampus of rats undergoing amygdala kindling: implications for antiepileptogenic and mood-stabilizing properties , 2004, Epilepsy & Behavior.

[23]  M. Strolin Benedetti,et al.  Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[24]  C. Wasterlain,et al.  Anticonvulsant effects of levetiracetam and levetiracetam–diazepam combinations in experimental status epilepticus , 2004, Epilepsy Research.

[25]  W. Löscher,et al.  Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats , 2004, Epilepsy Research.

[26]  P. Calabresi,et al.  Levetiracetam protects against kainic acid-induced toxicity. , 2004, Life sciences.

[27]  W. Löscher,et al.  The antiepileptic drug levetiracetam selectively modifies kindling‐induced alterations in gene expression in the temporal lobe of rats , 2004, European Journal of Neuroscience.

[28]  R. Post,et al.  Unidirectional Cross‐tolerance from Levetiracetam to Carbamazepine in Amygdala‐kindled Seizures , 2003, Epilepsia.

[29]  D. Margineanu,et al.  Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? , 2003, Neuropharmacology.

[30]  R. Finnell,et al.  Developmental Outcome of Levetiracetam, Its Major Metabolite in Humans, 2‐Pyrrolidinone N‐Butyric Acid, and Its Enantiomer (R)‐α‐ethyl‐oxo‐pyrrolidine Acetamide in a Mouse Model of Teratogenicity , 2003, Epilepsia.

[31]  B. Lynch,et al.  Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. , 2003, European journal of pharmacology.

[32]  D. Margineanu,et al.  Desynchronizing effect of levetiracetam on epileptiform responses in rat hippocampal slices , 2003, Neuroreport.

[33]  E. Perucca,et al.  Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs , 2003, The Lancet Neurology.

[34]  D. Margineanu,et al.  Levetiracetam has no significant gamma-aminobutyric acid-related effect on paired-pulse interaction in the dentate gyrus of rats. , 2003, European journal of pharmacology.

[35]  S. Sisodiya.  Mechanisms of antiepileptic drug resistance , 2003, Current opinion in neurology.

[36]  E. Ben-Menachem,et al.  Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons , 2003, NeuroReport.

[37]  D. Margineanu,et al.  Electrophysiological, neurochemical and regional effects of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy , 2003, Seizure.

[38]  C. Large,et al.  Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model , 2003, Epilepsy Research.

[39]  A. Ebner,et al.  Effect of Levetiracetam on Epileptiform Discharges in Human Neocortical Slices , 2002, Epilepsia.

[40]  J. Olney,et al.  Antiepileptic drugs and apoptotic neurodegeneration in the developing brain , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  B Malgrange,et al.  The anti‐epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA‐ and glycine‐gated currents , 2002, British journal of pharmacology.

[42]  Wolfgang Löscher,et al.  Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. , 2002, The Journal of pharmacology and experimental therapeutics.

[43]  W. Löscher,et al.  Effects of the Novel Antiepileptic Drug Levetiracetam on Spontaneous Recurrent Seizures in the Rat Pilocarpine Model of Temporal Lobe Epilepsy , 2002, Epilepsia.

[44]  D. Margineanu,et al.  Levetiracetam opposes the action of GABAA antagonists in hypothalamic neurones , 2002, Neuropharmacology.

[45]  M. Whittington,et al.  A comparison of the efficacy of carbamazepine and the novel anti‐epileptic drug levetiracetam in the tetanus toxin model of focal complex partial epilepsy , 2002, British journal of pharmacology.

[46]  S. Spencer.  Neural Networks in Human Epilepsy: Evidence of and Implications for Treatment , 2002, Epilepsia.

[47]  V. Shkryl,et al.  Selective Blockade of N‐Type Calcium Channels by Levetiracetam , 2002, Epilepsia.

[48]  D. Limbrick,et al.  Epileptogenesis induces long-term alterations in intracellular calcium release and sequestration mechanisms in the hippocampal neuronal culture model of epilepsy. , 2001, Cell calcium.

[49]  H. Klitgaard.  Levetiracetam: The Preclinical Profile of a New Class of Antiepileptic Drugs? , 2001, Epilepsia.

[50]  Tao Xu,et al.  SV2 modulates the size of the readily releasable pool of secretory vesicles , 2001, Nature Cell Biology.

[51]  P. Patsalos,et al.  A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain , 2001, British journal of pharmacology.

[52]  D. Margineanu,et al.  Levetiracetam inhibits the high-voltage-activated Ca2+ current in pyramidal neurones of rat hippocampal slices , 2001, Neuroscience Letters.

[53]  H. Klitgaard,et al.  Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia , 2001, Seizure.

[54]  G. Bernardi,et al.  Levetiracetam does not modulate neuronal voltage-gated Na + and T-type Ca 2+ currents , 2001, Seizure.

[55]  W. Löscher,et al.  Development of Tolerance During Chronic Treatment of Kindled Rats With the Novel Antiepileptic Drug Levetiracetam , 2000, Epilepsia.

[56]  D. Margineanu,et al.  Absence of Negative Impact of Levetiracetam on Cognitive Function and Memory in Normal and Amygdala-Kindled Rats , 2000, Epilepsy & Behavior.

[57]  D. Margineanu,et al.  Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. , 2000, Pharmacological research.

[58]  W. Löscher,et al.  The new antiepileptic drugs lamotrigine and felbamate are effective in phenytoin-resistant kindled rats , 2000, Neuropharmacology.

[59]  P. Genton,et al.  Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. , 2000, Epileptic disorders : international epilepsy journal with videotape.

[60]  W. Löscher,et al.  Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats , 2000, Epilepsy Research.

[61]  W. Löscher,et al.  Repeated Acute Testing of Anticonvulsant Drugs in Amygdala Kindled Rats: Increase in Anticonvulsant But Decrease in Adverse Effect Potential , 2000, Epilepsia.

[62]  W. Löscher,et al.  Anticonvulsant Efficacy of Topiramate in Phenytoin‐Resistant Kindled Rats , 2000, Epilepsia.

[63]  Brian D. Hale,et al.  Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Markus Missler,et al.  SV2A and SV2B Function as Redundant Ca2+ Regulators in Neurotransmitter Release , 1999, Neuron.

[65]  O. Lindvall,et al.  Dynamic changes of brain-derived neurotrophic factor protein levels in the rat forebrain after single and recurring kindling-induced seizures , 1998, Neuroscience.

[66]  J. Gobert,et al.  Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. , 1998, European journal of pharmacology.

[67]  H. Klitgaard,et al.  Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man , 1998, Epilepsy Research.

[68]  W. Löscher,et al.  Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. , 1998, The Journal of pharmacology and experimental therapeutics.

[69]  D. Margineanu,et al.  Inhibition by levetiracetam of a non‐GABAA receptor‐associated epileptiform effect of bicuculline in rat hippocampus , 1997, British journal of pharmacology.

[70]  S. Beck,et al.  Levetiracetam (ucb LO59) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[71]  W. Löscher,et al.  The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata , 1996, Brain Research.

[72]  D. Margineanu,et al.  ucb L059, a novel anticonvulsant, reduces bicuculline-induced hyperexcitability in rat hippocampal CA3 in vivo. , 1995, European journal of pharmacology.

[73]  J. Hénichart,et al.  The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. , 1995, European journal of pharmacology.

[74]  C. Marescaux,et al.  Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy , 1995, Epilepsy Research.

[75]  W. Löscher,et al.  Pharmacological characterization of phenytoin-resistant amygdala-kindled rats, a new model of drug-resistant partial epilepsy , 1993, Epilepsy Research.

[76]  W. Löscher,et al.  Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. , 1993, European journal of pharmacology.

[77]  J. Gobert,et al.  ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. , 1992, European journal of pharmacology.

[78]  M. Feany,et al.  The synaptic vesicle protein SV2 is a novel type of transmembrane transporter , 1992, Cell.

[79]  T. Serikawa,et al.  Ontogeny of absence-like and tonic seizures in the spontaneously epileptic rat , 1991, Laboratory animals.

[80]  O. Lindvall,et al.  Increased levels of messenger RNAs for neurotrophic factors in the brain during kindling epileptogenesis , 1991, Neuron.

[81]  J. McNamara,et al.  Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilepsy , 1991, Annals of neurology.

[82]  D. Prince,et al.  Cellular and field potential properties of epileptogenic hippocampal slices , 1978, Brain Research.

[83]  J. Wada.  Pharmacological prophylaxis in the kindling model of epilepsy. , 1977, Archives of neurology.

[84]  Junling Gao,et al.  Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage , 2006, Neurocritical care.

[85]  A. El Idrissi,et al.  Prevention of epileptic seizures by taurine. , 2003, Advances in experimental medicine and biology.

[86]  P. Deyn,et al.  Protective effect of ucb L059 against postural stimulation-induced seizures in EL mice , 1992 .